ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 1

Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

February 28, 2025

Pedro C. Barata, MD, MSc, FACP , Moshe Ornstein, MD, Elizabeth Wulff-Burchfield, MD , Kathryn E. Beckermann, MD, PhD

Experts discuss the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plus ipilimumab for first-line treatment of advanced renal cell carcinoma (RCC), and how these mature overall survival (OS) data influence the view of nivolumab plus ipilimumab as a frontline option, alongside insights from efficacy, safety, post hoc subgroup analyses (Albiges et al, Eur Urol, 2022), and health-related quality of life (HRQOL) data (Cella et al, J Clin Oncol, 2022).

Now Viewing

EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

Video content above is prompted by the following:

Please walk us though the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plusipilimumab for first-line treatment of advanced RCC.
How do these mature OS data influence your view of nivolumab plusipilimumab as a frontline option?
Please share your insights from efficacy and safety data, post hoc subgroup analyses, or HRQOL data. How you interpret these data?